Interferon alpha-2b and thalidomide in previously treated patients with disseminated malignant melanoma: SWOG 0026.

被引：0
|
作者：
Hutchins, L
Moon, J
Clark, J
Thompson, J
Yost, K
Sondak, V
机构：
[1] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Grand Rapids CCOP, Grand Rapids, MI USA
[6] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：716S / 716S
页数：1
相关论文
共 50 条
  • [31] Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
    A Ravaud
    C Bedane
    L Geoffrois
    T Lesimple
    M Delaunay
    British Journal of Cancer, 1999, 80 : 1767 - 1769
  • [32] Pegylated Interferon Alpha-2B for the Management of Patients With Chronic Hepatitis Delta
    Gheorghe, Liana
    Iacab, Speranta
    Simionov, Iulia I.
    Vadan, Roxawa
    Constantinescu, Ileana
    Sporea, Ioan
    Grigotescu, Mircea D.
    GASTROENTEROLOGY, 2011, 140 (05) : S454 - S454
  • [33] EFFICIENCY OF ALPHA-2B INTERFERON IN THE TREATMENT OF HCV INFECTION IN HEMODIALYZED PATIENTS
    POL, S
    THIERS, V
    CARNOT, F
    ZINS, B
    ROMEO, R
    BERTHELOT, P
    BRECHOT, C
    HEPATOLOGY, 1994, 20 (04) : A160 - A160
  • [34] Neuropsychiatric complications of interferon-alpha-2b therapy of malignant melanoma
    Okereke, OI
    PSYCHOSOMATICS, 2002, 43 (02) : 147 - 147
  • [35] Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b
    Them, Nicole C. C.
    Bagienski, Klaudia
    Berg, Tiina
    Gisslinger, Bettina
    Schalling, Martin
    Chen, Doris
    Buxhofer-Ausch, Veronika
    Thaler, Josef
    Schloegl, Ernst
    Gastl, Guenther A.
    Wolf, Dominik
    Strecker, Karin
    Egle, Alexander
    Melchardt, Thomas
    Burgstaller, Sonja
    Willenbacher, Ella
    Zagrijtschuk, Oleh
    Klade, Christoph
    Greil, Richard
    Gisslinger, Heinz
    Kralovics, Robert
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (04) : 288 - 294
  • [36] PHASE-II TRIAL OF RECOMBINANT ALPHA-2B INTERFERON IN THE TREATMENT OF METASTATIC SKIN MELANOMA
    SERTOLI, MR
    BERNENGO, MG
    ARDIZZONI, A
    BRUNETTI, I
    FALCONE, A
    VIDILI, MG
    CUSIMANO, MP
    APPINO, A
    DOVEIL, G
    FORTINI, C
    ROSSO, R
    ONCOLOGY, 1989, 46 (02) : 96 - 98
  • [37] Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin
    Asahina, Y.
    Izumi, N.
    Umeda, N.
    Hosokawa, T.
    Ueda, K.
    Doi, F.
    Tsuchiya, K.
    Nakanishi, H.
    Matsunaga, K.
    Kitamura, T.
    Kurosaki, M.
    Uchihara, M.
    Higaki, M.
    Miyake, S.
    JOURNAL OF VIRAL HEPATITIS, 2007, 14 (06) : 396 - 403
  • [38] Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma
    Grignol, V. P.
    Olencki, T.
    Taylor, C.
    Kibler, A.
    Kefauver, C.
    Wei, L.
    Walker, M. J.
    Chen, H. X.
    Kendra, K. L.
    Carson, W. E., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Peg interferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in treatment-naive patients in Egypt
    Elwaki, M. R.
    Montasser, M. F.
    Mansour, M. A.
    Salman, T. A.
    El-Batanony, M. H.
    Helail, E. H.
    Shehata, K. O.
    Attallah, K. M.
    Madwar, M. A.
    LIVER INTERNATIONAL, 2006, 26 : 84 - 84
  • [40] Histological improvement in patients with pegylated interferon alpha-2b plus ribavirin who were previously non-responders to Rebetron
    Selim, K
    Hyun, C
    Jensen, J
    Rossi, SJ
    Lyche, K
    Weprin, L
    Oliver, D
    Myers, WY
    Ziegler, B
    Behling, C
    Hassanein, T
    GASTROENTEROLOGY, 2003, 124 (04) : A701 - A701
12345